Carprofen 50 mg, meat-flavoured divisible tablet for dogs
Assessed clinical scopeDog · Reduction of canine musculoskeletal and degenerative-joint pain and inflammation, plus up to five days of oral follow-up after parenteral preoperative analgesia · By mouth
Care settingVeterinary-directed home treatment after diagnosis and patient selection, with accurate weighing, response-guided dose reduction, toxicity counselling and periodic reassessment/monitoring
vetman score
8.0/10
Very good
Evidence confidence: High
Georgia: Yes, veterinary · № 145-11; 232-11 · Verified on 19 Oct 2026
A well-documented, evidence-supported oral canine NSAID and a very good standard option for appropriately selected osteoarthritis patients, with useful short postoperative follow-up use. Its value depends on diagnosis, the lowest effective response-guided dose, multimodal care, baseline risk assessment and prompt withdrawal if intolerance appears; it is not for cats and not a harmless routine analgesic.
Regulatory and scientific credibility9.0/10
Exact Rycarfa 50 mg has current regulator-hosted EU/UK product information, a named MA holder, authorisation number, dog-only indications, complete dosing and safety text, and two current Georgian registrations. FDA-authorised oral carprofen products provide an additional mature regulatory and pharmacovigilance comparator.
Clinical efficacy8.5/10
Multiple placebo-controlled and active-comparator canine studies consistently support oral carprofen for osteoarthritis pain and function, and current pain guidelines place NSAIDs among core high-impact options. The evidence is strongest for OA; product-label postoperative follow-up is useful but is not a stand-alone multimodal perioperative plan or a disease-modifying claim.
Safety and tolerability6.5/10
Correctly selected dogs often tolerate carprofen well and controlled trials did not show a large routine toxicity signal, but the therapeutic margin is not trivial. Gastrointestinal ulceration/bleeding, renal injury, idiosyncratic hepatic injury and rare serious or fatal reactions remain clinically important; organ disease, dehydration, pregnancy/lactation, young age and interacting anti-inflammatory drugs materially narrow safe use.
Clinical practicality8.0/10
Meat flavour, once-daily use, optional division of the initial daily amount and equal half-tablets make home treatment workable. Accurate weight-based selection is still limited by 25 mg half-tablet increments; the unused half must return to the blister and be used within 24 hours, and long-term treatment requires regular clinical and laboratory review.
Full-course cost-effectiveness-
Price was not assessed and is excluded from the overall score.
Important safety and use flags
- Verify exact Rycarfa 50 mg tablets for dogs. Do not transfer this score, half-tablet handling or dose to another carprofen brand, strength, chewable tablet, capsule or injection.
- Weigh accurately. Give 2-4 mg/kg/day; the initial 4 mg/kg daily amount may be given once or split into two equal doses and may be reduced after 7 days to 2 mg/kg once daily according to response. Use the lowest effective dose.
- Dog only. Do not use oral carprofen tablets in cats; feline clearance and therapeutic margin differ, and current Rycarfa/Rimadyl tablet labels explicitly prohibit feline use.
- Before treatment, obtain a thorough history and examination and consider baseline CBC, serum biochemistry and urinalysis. Reassess pain, function, hydration, blood pressure and renal/hepatic variables periodically, especially in older dogs or long courses.
- Stop treatment and assess promptly for appetite loss, vomiting, diarrhoea, melena or hematemesis, lethargy, behaviour change, PU/PD, pallor, jaundice, ataxia, seizure, oedema or other suspected intolerance; rare serious or fatal reactions can occur without warning.
- Do not combine with another NSAID or a glucocorticoid and do not give either within at least 24 hours of Rycarfa. Select any longer washout from the previous drug’s pharmacokinetics and the patient’s condition; use non-NSAID rescue analgesia if needed.
- Avoid in dehydration, hypovolaemia or hypotension and in cardiac, hepatic or renal disease, gastrointestinal ulceration/bleeding risk or blood dyscrasia. Avoid potentially nephrotoxic drugs and closely review highly protein-bound or similarly metabolised medicines.
- Do not use in pregnant or lactating bitches, dogs under 4 months, or patients hypersensitive to carprofen/NSAIDs or excipients. Use in aged dogs adds risk and requires careful management.
- The 50 mg tablet divides only into equal halves. Return the unused half to the opened blister, use it within 24 hours, protect from light/moisture and prevent accidental ingestion of the flavoured tablets.
- For chronic osteoarthritis, combine medicine with weight management, appropriate exercise/rehabilitation and other case-specific modalities. Reassess benefit regularly; carprofen controls pain and inflammation but does not modify the underlying joint disease.
Assessment sources+
